Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Giral

Showing results (1-10 of 118) with videos related to

Pageof 12
Sort By:
La Revue Du Praticien|October 22, 1998
[Atheroma]P Giral
Therapie|March 10, 2001
[Prevention of cardiovascular diseases in elderly subjects with hypercholesterolemia]E Bruckert, P Giral
La Revue Du Praticien|June 8, 1989
[Triglycerides and hemostasis]E Bruckert, P Giral
The New England Journal of Medicine|February 6, 1992
Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factorP Giral, E Bruckert
Journal of Clinical Epidemiology|July 17, 1999
Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study TeamE Bruckert, C Simonetta, P Giral
Circulation|September 15, 1995
Extracoronary atherosclerotic plaque at multiple sites and total coronary calcification deposit in asymptomatic men. Association with coronary risk profileA Simon, P Giral, J Levenson
JAMA|May 2, 1990
Système international units and familiar formulas: the case of lipidsP Giral, E Bruckert, H Boyer
Presse Medicale (Paris, France : 1983)|March 7, 2001
[Hyperlipidemias: new data and new concepts]E Bruckert, P Giral, G Turpin
European Journal of Pharmacology|January 28, 1987
Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systemsP Giral, P Soubrie, A J Puech
Thrombosis and Haemostasis|September 1, 1994
Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patientsE Bruckert, A Ankri, P Giral, et al.
Pageof 12

Showing results (1-10 of 118) with videos related to

Sort By:
Pageof 12
La Revue Du Praticien|October 22, 1998
[Atheroma]P Giral
Therapie|March 10, 2001
[Prevention of cardiovascular diseases in elderly subjects with hypercholesterolemia]E Bruckert, P Giral
La Revue Du Praticien|June 8, 1989
[Triglycerides and hemostasis]E Bruckert, P Giral
The New England Journal of Medicine|February 6, 1992
Ratio of low-density lipoprotein cholesterol to ubiquinone as a coronary risk factorP Giral, E Bruckert
Journal of Clinical Epidemiology|July 17, 1999
Compliance with fluvastatin treatment characterization of the noncompliant population within a population of 3845 patients with hyperlipidemia. CREOLE Study TeamE Bruckert, C Simonetta, P Giral
Circulation|September 15, 1995
Extracoronary atherosclerotic plaque at multiple sites and total coronary calcification deposit in asymptomatic men. Association with coronary risk profileA Simon, P Giral, J Levenson
JAMA|May 2, 1990
Système international units and familiar formulas: the case of lipidsP Giral, E Bruckert, H Boyer
Presse Medicale (Paris, France : 1983)|March 7, 2001
[Hyperlipidemias: new data and new concepts]E Bruckert, P Giral, G Turpin
European Journal of Pharmacology|January 28, 1987
Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systemsP Giral, P Soubrie, A J Puech
Thrombosis and Haemostasis|September 1, 1994
Relation between plasminogen activator inhibitor-1 and hepatic enzyme concentrations in hyperlipidemic patientsE Bruckert, A Ankri, P Giral, et al.
Pageof 12